Tekmira Pharma (TKMR) Posts Wider than Expected Q2 Loss of 28c/Share; Expects FDA Hold to Resolved by Q4 2014

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. STUB
6. EAT
7. BTGO
8. NVDA
9. WYFI
10. ARX

Go back to Tekmira Pharma (TKMR) Posts Wider than Expected Q2 Loss of 28c/Share; Expects FDA Hold to Resolved by Q4 2014

Tekmira Provides Corporate Update and Announces Second Quarter 2014 Results

August 13, 2014 4:30 PM EDT

VANCOUVER, British Columbia, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR) (TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its financial and operating results for the second quarter ended June 30, 2014 and provided a corporate update.

"We continue to monitor the tragic Ebola virus outbreak very closely. The current outbreak underscores the critical need for an effective therapeutic agent to treat the Ebola virus,"said Dr. Mark J. Murray, Tekmira's President and CEO.

"We remain sharply focused on our clinical... More